financetom
Business
financetom
/
Business
/
Update: Market Chatter: Moderna Wins Patent Ruling Against Pfizer, BioNTech in German Court
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Market Chatter: Moderna Wins Patent Ruling Against Pfizer, BioNTech in German Court
Mar 6, 2025 11:34 AM

02:28 PM EST, 03/06/2025 (MT Newswires) -- (Updates with Moderna ( MRNA ) and BioNTech's responses in the fifth and sixth paragraphs, along with the latest stock move in the last paragraph.)

Pfizer ( PFE ) and its partner BioNTech (BNTX) have infringed a COVID-19 vaccine patent owned by Moderna ( MRNA ) , Reuters reported Wednesday, citing a German court ruling.

The court reportedly ordered Pfizer ( PFE ) and BioNTech to disclose earnings related to the patent's use and pay a compensation to Moderna ( MRNA ), according to the report.

Pfizer ( PFE ) and BioNTech argued they were permitted to use the technology based on Moderna's ( MRNA ) public statement until the World Health Organization declared in May 2023 that COVID-19 was no longer a global emergency, the media outlet reported.

The court did not determine the compensation amount, which will be decided in further legal proceedings and could change if there is an appeal, Reuters said.

A Moderna ( MRNA ) spokesperson told MT Newswires that the company is "pleased with the Court's decision," adding that the company will continue to pursue intellectual property rights.

"It is important to note that an appeal to the European Patent Office's Technical Board of Appeal regarding the ongoing opposition to this patent is pending," a BioNTech spokesperson told MT Newswires. "Today's decision has no immediate impact on Pfizer ( PFE ), BioNTech, or Comirnaty. We continue to believe that EP949 is invalid, and therefore not infringed, and will appeal the Dusseldorf District Court's decision on this patent."

Pfizer ( PFE ) did not immediately respond to requests for comment from MT Newswires.

Shares of Pfizer ( PFE ) were up about 1.5% in recent trading, while BioNTech and Moderna's ( MRNA ) stock was down 3% and 2.8%, respectively.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 26.35, Change: +0.41, Percent Change: +1.58

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
India Mobile Congress: PM Modi lauds India's 5G success, says country will lead the world on 6G
India Mobile Congress: PM Modi lauds India's 5G success, says country will lead the world on 6G
Oct 27, 2023
India Mobile Congress: PM Modi expressed confidence that India would lead the world in 6G technology. He pointed out the social and economic implications of improved internet connectivity and speed, such as better education access, telehealth for patients, and advanced farming techniques for farmers.
Optiemus Infracom plans to manufacture Corning Gorilla glass in India by 2024
Optiemus Infracom plans to manufacture Corning Gorilla glass in India by 2024
Oct 28, 2023
In September, Optiemus Infracom and Corning International Corporation unveiled a 70:30 joint venture aimed at establishing India's inaugural manufacturing plant for crafting high-quality finished cover glass components for the mobile consumer electronics sector.
Dassault Systemes raises profit forecast following robust Q3 subscriptions
Dassault Systemes raises profit forecast following robust Q3 subscriptions
Oct 25, 2023
This was driven by an 18% rise in subscription revenues due to an increasing share of large 3DEXPERIENCE contracts and a broad-based adoption of a subscription model, the company said.
KPMG CEO Outlook 2023 survey: Investing in generative artificial intelligence top priority for business leaders
KPMG CEO Outlook 2023 survey: Investing in generative artificial intelligence top priority for business leaders
Oct 23, 2023
Investing in generative artificial intelligence (Gen-AI) has emerged as the top priority for CEOs around the world, according to the recently released KPMG CEO Outlook 2023 survey. Despite the concerns regarding geopolitical and environmental challenges, CEOs across the world, including those in India, remain optimistic about their growth prospects. They see opportunities in mergers and acquisitions (M&A) as a means to enhance their market presence and capabilities.
Copyright 2023-2026 - www.financetom.com All Rights Reserved